Microbot Medical Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting Acceptance reflects the high interest of the SIR scientific committee on the emerging role of endovas

Medical Announces Late-Breaking Abstract

Acceptance at the Society of Interventional Radiology Annual Meeting

reflects the high interest of the SIR scientific committee on the emerging role of endovascular robotics

Mass., February 4, 2025 - Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular

Robotic System, today announced the acceptance of a late-breaking abstract that will be presented at the upcoming Society of Interventional

Radiology (SIR) annual meeting, being held in Nashville, TN on March 29 - April 2, 2025. The data from the Company's ACCESS-PVI

trial, a prospective, multicenter, single-arm trial evaluating the performance and safety of LIBERTY in patients undergoing

peripheral vascular interventions, will be presented for the first time at a podium presentation.

believe the acceptance of this late breaking news is critically important and allows the Principal Investigators (PI) to present the

data for the first time at the SIR annual meeting, especially since the primary attendees at this conference are potential users of LIBERTY ,"

commented Harel Gadot, Chairman, CEO and President. "In addition, we believe that the potential benefits of LIBERTY will

be meaningful and significant to the audience."

Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions

of patients and providers globally. The Company has developed the world's first single-use, fully disposable endovascular robotic

system, which aims to eliminate traditional barriers to accessing advanced robotic systems.

information about Microbot Medical is available at http://www.microbotmedical.com.

to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential

opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals,

plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation

Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements

that contain words such as "will," "believes," "plans," "anticipates," "expects"

and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and

uncertainties, including, without limitation, the Company's need for and ability to obtain additional working capital to continue

its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the

LIBERTY Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including

whether the FDA will grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United

States, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and

maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under

the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and Exchange Commission

(SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical disclaims any intent or obligation

to update these forward-looking statements, except as required by law.

Contact: IR@microbotmedical.com